Related Experiment Video
Updated: Jan 26, 2026

Author Spotlight: A Computational Pipeline for Analyzing Chimeric Noncoding RNA-Target RNA Interactions in High-Throughput Sequencing Data
Published on: December 1, 2023
Mechanism mediated by a noncoding RNA, nc886, in the cytotoxicity of a DNA-reactive compound
Nawapol Kunkeaw1,2, Yeon-Su Lee3, Wonkyun Ronny Im4
1Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555-1072.
Abstract:
DNA-reactive compounds are harnessed for cancer chemotherapy. Their genotoxic effects are considered to be the main mechanism for the cytotoxicity to date. Because this mechanism preferentially affects actively proliferating cells, it is postulated that the cytotoxicity is specific to cancer cells. Nonetheless, they do harm normal quiescent cells, suggesting that there are other cytotoxic mechanisms to be uncovered. By employing doxorubicin as a representative DNA-reactive compound, we have discovered a cytotoxic mechanism that involves a cellular noncoding RNA (ncRNA) nc886 and protein kinase R (PKR) that is a proapoptotic protein. nc886 is transcribed by RNA polymerase III (Pol III), binds to PKR, and prevents it from aberrant activation in most normal cells. We have shown here that doxorubicin evicts Pol III from DNA and, thereby, shuts down nc886 transcription. Consequently, the instantaneous depletion of nc886 provokes PKR and leads to apoptosis. In a short-pulse treatment of doxorubicin, these events are the main cause of cytotoxicity preceding the DNA damage response in a 3D culture system as well as the monolayer cultures. By identifying nc886 as a molecular signal for PKR to sense doxorubicin, we have provided an explanation for the conundrum why DNA-damaging drugs can be cytotoxic to quiescent cells that have the competent nc886/PKR pathway.
Insights
Doxorubicin triggers apoptosis in cancer cells via a novel pathway involving nc886 noncoding RNA and protein kinase R (PKR). This mechanism explains how DNA-damaging chemotherapy drugs harm normal cells, preceding DNA damage responses.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- DNA-reactive compounds are key in cancer chemotherapy, primarily through genotoxicity.
- Their cytotoxicity is thought to target rapidly dividing cancer cells, but they also affect normal cells.
- This suggests additional cytotoxic mechanisms beyond DNA damage.
Purpose of the Study:
- To uncover alternative cytotoxic mechanisms of DNA-reactive chemotherapy agents.
- To investigate the role of noncoding RNA (ncRNA) and protein kinase R (PKR) in doxorubicin-induced cytotoxicity.
- To explain the toxicity of DNA-damaging drugs in normal quiescent cells.
Main Methods:
- Utilized doxorubicin as a model DNA-reactive compound.
- Investigated the interaction between nc886 ncRNA, PKR, and RNA polymerase III (Pol III).
- Examined cellular responses in 3D and monolayer culture systems following short-pulse doxorubicin treatment.
Main Results:
- Doxorubicin disrupts Pol III binding to DNA, inhibiting nc886 transcription.
- This leads to rapid nc886 depletion, activating PKR and inducing apoptosis.
- This ncRNA/PKR pathway activation precedes DNA damage response, explaining cytotoxicity in quiescent cells.
Conclusions:
- Identified a novel doxorubicin-induced cytotoxic pathway mediated by nc886 ncRNA and PKR.
- nc886 acts as a molecular sensor for doxorubicin, triggering apoptosis via PKR.
- This pathway provides a mechanism for DNA-damaging drug toxicity in normal quiescent cells.
Related Concept Videos
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
RNA Polymerase II Accessory Proteins
Organic Compounds
RNA Stability
Drug Absorption Mechanism: Carrier-Mediated Membrane Transport
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...

